Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825318 | 1.00 | BACE1 (0.62) | BACE1DHFR | |
| SCHEMBL15839677 | 0.85 | BACE1 (0.72) | BACE1DHFR | |
| SCHEMBL17260317 | 0.85 | BACE1 (0.72) | BACE1DHFR | |
| SCHEMBL15825663 | 0.83 | BACE1 (0.64) | BACE1DHFR | |
| SCHEMBL15825491 | 0.83 | BACE1 (0.64) | BACE1DHFR | |
| SCHEMBL17264651 | 0.83 | BACE1 (0.64) | BACE1DHFR | |
| SCHEMBL17264649 | 0.83 | BACE1 (0.64) | BACE1DHFR | |
| SCHEMBL15839659 | 0.81 | BACE1 (0.70) | BACE1 | |
| SCHEMBL15839629 | 0.81 | BACE1 (0.70) | BACE1 | |
| SCHEMBL15825543 | 0.81 | BACE1 (0.70) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475784-B2 | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475784-B2 | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BACE1, APP, BACE2 | BACE1 1/4885DHFR 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.